The safety, efficacy, pharmacokinetics, and pharmacodynamics of the anti-programmed cell death-1 antibody MEDI0680 were evaluated in a phase I, multicenter, dose-escalation study in advanced solid malignancies. The authors conclude that MEDI0680 induced peripheral T-cell proliferation and...
Immune checkpoint inhibitors (ICI) have demonstrated remarkable efficacy as cancer therapeutics, however, their use remains limited due to the development of immune related adverse events (irAEs). Immune related enterocolitis (irEC) is among the most common severe irAEs leading to the...
Pembrolizumab is a potent, humanized, monoclonal anti–programmed death 1 antibody that has demonstrated effective antitumor activity and acceptable safety in multiple tumor types. Therapeutic biologics can result in the development of antidrug antibodies (ADAs), which may alter drug clearance...
Immune checkpoint inhibitors (ICIs) have now become standard of care treatment for many malignancies. ICIs are associated with unique immune mediated adverse events (irAEs) due to dysregulation of immune activation. As treatment with ICIs is becoming more common, rare irAEs are also being...
On Aug. 28, 2019, at Noon EDT, please join leading experts for a presentation of the latest advances in cancer immunotherapy emerging from the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting. Click here to register now ! The webinar will summarize key studies on the...
08-28-2019 | 12:00 - 13:00 ET
On July 24, 2019, leading experts in cancer immunotherapy presented an overview of the publication " The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC) " at a live webinar. The recorded webinar...
2 attachments
The Society for Immunotherapy of Cancer (SITC) is excited to announce the participants of the inaugural SITC Women in Cancer Immunotherapy Network (WIN) Leadership Institute, scheduled for Aug. 19-20, 2019, in Seattle, Wash. Kristin G. Anderson, PhD, Fred Hutchinson Cancer Research...
This webinar provided an update on developments in the field relating to content presented at the Advances in Cancer Immunotherapy programs and focused on applicable information for a clinical audience. This webinar focuses on the lat est clinical trials presented during ESMO Immuno-Oncology...
With cutting-edge data regularly emerging from conferences and new FDA approvals, keeping updated with the latest cancer immunotherapy research is an arduous task for a practicing clinician. To complement and expand upon the live Advances in Cancer Immunotherapy™ (ACI) programs, SITC is proud to...
Join
Renew
Member Directory
My Profile
Email Sign-up
Volunteer
Support SITC
Contact Us